share_log

Morgan Stanley Upgrades Third Harmonic Bio to Overweight, Raises Price Target to $20

Morgan Stanley Upgrades Third Harmonic Bio to Overweight, Raises Price Target to $20

摩根士丹利將Third Harmonic Bio評級升級至超配,將目標股價上調至20美元。
Benzinga ·  08/09 04:28  · 評級/大行評級

Morgan Stanley analyst Michael Ulz upgrades Third Harmonic Bio (NASDAQ:THRD) from Equal-Weight to Overweight and raises the price target from $12 to $20.

摩根士丹利分析師邁克爾・烏爾茲將Third Harmonic Bio (NASDAQ:THRD) 的評級從Equal-Weight升級至Overweight,並將目標價從12美元升至20美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論